InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,306.04
(
0.02%
)
US TECH 100
18,375.20
(
0.31%
)
Dow Jones
38,852.86
(
-0.55%
)
Brent Oil
84.18
(
-0.18%
)
Bitcoin
68,664.02
(
0.55%
)
Post# of 251952
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119702
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Titan V post# 211837

Wednesday, 07/05/2017 4:58:37 PM

Wednesday, July 05, 2017 4:58:37 PM

Post# of 251952
MRK—FDA places clinical hold on Keytruda trials in MM:

https://finance.yahoo.com/news/merck-provides-further-three-multiple-203000739.html

The FDA has determined that the data available at the present time indicate that the risks of KEYTRUDA plus pomalidomide or lenalidomide outweigh any potential benefit for patients with multiple myeloma. All patients enrolled in KEYNOTE-183 and KEYNOTE-185 and those in the KEYTRUDA/lenalidomide/dexamethasone cohort in KEYNOTE-023 will discontinue investigational treatment with KEYTRUDA.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up